Korean J Med.  2014 Jun;86(6):695-697.

Strategy to Manage Irritable Bowel Syndrome in Korea

• Kim JH
• Sung IK

Abstract

Irritable bowel syndrome (IBS) is one of the most prevalent functional gastrointestinal disorders. It is a multi-factorial disorder due to abnormal gastrointestinal motility, low-grade inflammation, visceral hypersensitivity, and communication between the gut-brain axis. IBS is traditionally treated with dietary and lifestyle modifications, fiber supplementation, and psychological and pharmacological therapies. Diet therapy including the low FODMAP diet and excluding certain food constituents is often used. Antispasmodics plus stool consistency modifiers to treat the major symptoms and defecation are first-line drug treatments. 5-Hydroxytryptamine (5-HT) receptors in the gastrointestinal tract, particularly 5-HT3 and 5-HT4 receptors are involved not only in modulating gut motility but in visceral sensory pathways. Drugs that act on both receptor classes appear to reduce visceral sensitivity and have inhibitory effects on motor activity in the distal intestine. 5-HT4 agonists may improve constipation-predominant IBS by normalizing bowel habits and thereby reduce abdominal pain. IBS continues to be a therapeutic challenge because of its diverse symptomatology and lack of a single pathophysiological target for drug intervention.

Keyword

Irritable bowel syndrome; low FODMAP diet; 5-HT4 agonists

MeSH Terms

Abdominal Pain
Axis, Cervical Vertebra
Defecation
Diet
Diet Therapy
Gastrointestinal Diseases
Gastrointestinal Motility
Gastrointestinal Tract
Hypersensitivity
Inflammation
Intestines
Irritable Bowel Syndrome*
Korea
Life Style
Motor Activity
Parasympatholytics
Receptors, Serotonin, 5-HT4
Serotonin
Serotonin 5-HT4 Receptor Agonists
Parasympatholytics
Receptors, Serotonin, 5-HT4
Serotonin
Serotonin 5-HT4 Receptor Agonists